(
out of
98
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Hospital South
Clinic 2B, Neuro-Oncology
1950 Circle of Hope
Salt Lake City
,
UT
84112
Board Certification
|
American Board of Psychiatry & Neurology (Neurology)
United Council for Neurologic Subspecialties (Neuro-oncology)
|
Patient Rating
Patients consistently praise Dr. Colman and his team for strong expertise, clear explanations, and for reviewing MRI images and treatment rationale during visits. Reviewers frequently note compassionate, thorough, and collaborative care from the physician, PA, and nursing staff, saying the communication often restored hope and confidence. A minority of comments mention occasional rushed interactions or a missed scan review that prompted one patient to seek a second opinion.
Generated via Patient Reviews
4.8
/5
( out of
98 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Neurology
-Adjunct Professor Neurosurgery -Professor Internal Medicine -Adjunct Professor |
|---|---|
| Academic Divisions |
Oncology
|
| Board Certification |
American Board of Psychiatry & Neurology (Neurology)
United Council for Neurologic Subspecialties (Neuro-oncology)
|
Education history
| Undergraduate | Neural Sciences - Brown University | Sc.B. |
|---|---|---|
| Doctoral Training | Neuroscience - Washington University School of Medicine | Ph.D. |
| Professional Medical | Medicine - Washington University School of Medicine | M.D. |
| Internship | Medicine - Barnes-Jewish Hospital, Washington University School of Medicine | Intern |
| Residency | Neurology - Barnes-Jewish Hospital, Washington University School of Medicine | Resident |
| Chief Resident | Neurology - Washington University School of Medicine | Chief Resident |
| Fellowship | Neuro-Oncology - University of Texas M.D. Anderson Cancer Center | Fellow |
Selected Publications
Journal Article
- Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW, Strowd RE, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth PA, Hamza MA, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann EJ, Welsh LC, Wen PY, Dietrich J, Wang C, Levin V (2026). STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. Journal of clinical oncology, 44(8), 641-652.
- Jones RL, Groisberg R, Blay JY, Colman H, De La Fuente M, Roxburgh P, Chao MM, Tian H, Duffaud F, Bahleda R, Van Tine B (2026). Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial. Nature communications, 17(1), 2224.
- Wen PY, Berry DA, Buxton MB, Colman H, de Groot J, Lim M, Mellinghoff I, Perry JR, Weller M, Blondin NA, Butt OH, Damek DM, de la Fuente MI, Drappatz J, Dunbar E, Giglio P, Hyddmark EV, Iwamoto F, Jaeckle KA, Kim L, Kling HM, Lee EQ, Mantica M, Mikkelsen T, Nabors B, Newton HB, Olson JJ, Schiff D, Walbert T, Weathers SP, Cloughesy T, Lassman AB, GBM AGILE Regorafenib Study Grou (2026). Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. Journal of clinical oncology, 44(18), 1676-1686.
- Keiser DJ, Buddy MS, Mojarad-Jabali S, Li Q, Kohler-Skinner M, Parrish AG, Gillespie D, Nix D, Holmen S, Colman H, Couldwell W, Jensen R, Szulzewsky (2026). Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines. bioRxiv,
- Underhill HR, Sellers DL, Hellwig S, Baradaran H, Bronner MP, Thomas A, Menacho S, Davidson CJ, Malani R, Farrell A, Karsy M, Nix DA, Zhang Y, Boatz LA, Mendez J, Burt L, Cannon D, Dean CS, Harrison BE, Stevenson S, Aitken K, Pulst SM, Colman H, Jensen R (2026). Molecular features unique to circulating tumor DNA enable the tumor-naïve liquid biopsy of glioblastoma. NPJ precision oncology,
- Rudra Gupta T, Polley MC, Redd R, Lee EQ, Arrillaga-Romany I, Gilbert MR, Tan Y, Touat M, Drappatz J, Welch MR, Galanis E, Ahluwalia MS, Colman H, Nabors LB, Hepel J, Elinzano H, Schiff D, Chukwueke UN, Beroukhim R, Nayak L, McFaline-Figueroa JR, Batchelor TT, Kaley TJ, Lu-Emerson C, Mellinghoff IK, Bi WL, Arnaout O, Peruzzi PP, Haas-Kogan D, Tanguturi S, Aizer A, Doherty L, Santagata S, Meredith DM, Chiocca EA, Reardon DA, Ligon KL, Weller M, Mehta MP, Wen PY, Trippa L, Rahman (2026). Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data. Journal of clinical oncology, JCO2501586.
- Hoobler R, Maschek JA, Luo B, Murphy EA, Kubinak JL, Stewart PA, Cox JE, Chaix A, Woodruff K, Sanchez A, Coletta AM, Tabung FK, Gupta S, Hardikar S, Colman H, Playdon M (2026). Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a cross-sectional analysis. The Journal of nutrition, 101603.
- Kurudza E, Varady SRS, Greiner D, Marvin JE, Ptacek A, Rodriguez M, Mishra AK, He G, Dotti G, Colman H, Reeves MQ, Montell DJ, Cheshier SH, Johnson M (2026). NG2-targeting macrophages inhibit 3D invasion of patient-derived glioblastoma spheroids. bioRxiv,
- Piotrowski AF, Shih K, Giglio P, Colman H, Wen PY, Campian JL, Butowski N, Cloughesy T, Zhu Z, Gisin V, Badruddoja (2025). Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma. Current oncology (Toronto, Ont.), 32(10), 541.
- Winn M, Pauleck S, Richardson S, Viskochil R, Karra P, Colman H, Doherty JA, Xu Y, Hu-Lieskovan S, Litchman M, Playdon MC, Hardikar (2025). New-onset prediabetes/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study. Diabetes, obesity & metabolism, 2025(2), 1-11.
- Wang X, Li T, Eljilany I, Soupir A, Radmacher M, Agius P, Sukrithan V, Ratan A, McCarter M, Salhia B, Colman H, Naqash AR, Puzanov I, Arnold S, Marin-Acevedo JA, Ganesan S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini A (2025). Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Nature communications, 16(1), 9968.
- Jhandi S, Jhandi AS, Cannon DM, Burt LM, DeCesaris C, Menacho ST, Colman H, Jensen R (2025). Stereotactic radiosurgery for radiation'induced meningiomas: long'term institutional outcomes with patient- and lesion'level analyses and an updated meta'analysis. Journal of neuro-oncology, 176(1), 122.
- Aßmann E, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D,Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Branes CA, Matsen C, Ma DS, Colman H, Hunt JP,Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Ott o AK,Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic . Journal of Behavioral Medicine, 47(3), 405-421.
- Underhill HR, Karsy M, Davidson CJ, Hellwig S, Stevenson S, Goold EA, Vincenti S, Sellers DL, Dean C, Harrison BE, Bronner MP, Colman H, Jensen R (2024). Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas. Cancer research, 84(7), 1149-1164.
- Arnold LM, Hoshina Y, Lee H, Colman H, Mendez (2024). Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors. Journal of neuro-oncology, 167(1), 211-217.
- Demetriou AN, Chow F, Craig DW, Webb MG, Ormond DR, Battiste J, Chakravarti A, Colman H, Villano JL, Schneider BP, Liu JKC, Churchman ML, Zada (2024). Profiling the molecular and clinical landscape of glioblastoma utilizing the Oncology Research Information Exchange Network brain cancer database. Neuro-oncology advances, 6(1), vdae046.
- McKean WB, Yang J, Boucher K, Shrieve DC, Suneja G, Salzman K, Jensen R, Cohen AL*, Colman H* (*Equal Contribution (2024). D-TERMINED, a phase 1 trial in newly diagnosed high-grade glioma with temozolomide, radiation, and minocycline followed by adjuvant minocycline/temozolomide. Neuro-oncology advances, 6(1), vdae063.
- Ose DJ, Adediran E, Mark B, Ocier K, Dunson WA Jr, Turner C, Taylor B, Svoboda K, Post AR, Leiser J, Colman H, Ulrich CM, Hashibe (2024). The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort study. Cancer medicine, 13(20), e70246.
- Wang X, Li T, Eljilany I, Sukrithan V, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini A (2024). Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. medRxiv, Preprint,
- Conway K, Edmiston SN, Vondras A, Reiner A, Corcoran DL, Shen R, Parrish EA, Hao H, Lin L, Kenney JM, Ilelaboye G, Kostrzewa CE, Kuan PF, Busam KJ, Lezcano C, Lee TK, Hernando E, Googe PB, Ollila DW, Moschos S, Gorlov I, Amos CI, Ernstoff MS, Cust AE, Wilmott JS, Scolyer RA, Mann GJ, Vergara IA, Ko J, Rees JR, Yan S, Nagore E, Bosenberg M, Rothberg BG, Osman I, Lee JE, Saenger Y, Bogner P, Thompson CL, Gerstenblith M, Holmen SL, Funchain P, Brunsgaard E, Depcik-Smith ND, Luo L, Boyce T, Orlow I, Begg CB, Berwick M, Thomas NE; InterMEL Study Grou (2024). DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO precision oncology, 8, e2400375.
- Eljilany I, Coleman S, Tan AC, McCarter MD, Carpten J, Colman H, Naqash AR, Puzanov I, Arnold SM, Churchman ML, Spakowicz D, Salhia B, Marin J, Ganesan S, Ratan A, Shriver C, Hwu P, Dalton WS, Weiner GJ, Conejo-Garcia JR, Rodriguez P, Tarhini A (2024). Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy. Cells, 13(23), 1993.
- Mendez JS, Cohen AL, Eckenstein M, Jensen RL, Burt LM, Salzman KL, Chamberlain M, Hsu HH, Hutchinson M, Iwamoto F, Ligon KL, Mrugala MM, Pelayo M, Plotkin SR, Puduvalli VK, Raizer J, Reardon DA, Sterba M, Walbert T, West BL, Wong ET, Zhang C, Colman (2024). Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Neuro-oncology advances, 6(1), vdae202.
- Tarhini AA, Hedges D, Tan AC, Rodriguez P, Sukrithan V, Ratan A, McCarter MD, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold SM, Churchman ML, Hwu P, Conejo-Garcia JR, Dalton WS, Weiner GJ, Eljilany (2024). Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers. Journal of oncology research and therapy, 9(2),
- Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Neil EC, Chakravarti A, Willmarth N, Balajonda BC, Menon J, Ma J, Bauer H, Nelson RS, Tan MS, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner (2023). Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study. Future oncology (London, England), 19(2), 173-188.
- Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh (2023). Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature medicine, 29(6), 1370-1378.
- Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw (2023). Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nature medicine, 29(10), 2402-2405.
- Earl ER, Colman H, Mendez J, Jensen RL, Karsy (2023). An evaluation of biobanking and therapeutic clinical trial representation among adult glioma patients from rural and urban Utah. Neuro-oncology practice, 10(5), 472-481.
- Rahman R, Trippa L, Lee EQ, Arrillaga-Romany I, Fell G, Touat M, McCluskey C, Wiley J, Gaffey S, Drappatz J, Welch MR, Galanis E, Ahluwalia MS, Colman H, Nabors LB, Hepel J, Elinzano H, Schiff D, Chukwueke UN, Beroukhim R, Nayak L, McFaline-Figueroa JR, Batchelor TT, Rinne ML, Kaley TJ, Lu-Emerson C, Mellinghoff IK, Bi WL, Arnaout O, Peruzzi PP, Haas-Kogan D, Tanguturi S, Cagney D, Aizer A, Doherty L, Lavallee M, Fisher-Longden B, Dowling S, Geduldig J, Watkinson F, Pisano W, Malinowski S, Ramkissoon S, Santagata S, Meredith DM, Chiocca EA, Reardon DA, Alexander BM, Ligon KL, Wen P (2023). Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Journal of clinical oncology, 41(36), 5524-5535.
- Eljilany I, Saghand PG, Chen J, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Conejo-Garcia J, Dalton WS, Weiner GJ, El Naqa IM, Tarhini A (2023). The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors. Cancers, 15(20), 4913.
- Seong CS, Huang C, Boese AC, Hou Y, Koo J, Mouw JK, Rupji M, Joseph G, Johnston HR, Claussen H, Switchenko JM, Behera M, Churchman M, Kolesar JM, Arnold SM, Kerrigan K, Akerley W, Colman H, Johns MA, Arciero C, Zhou W, Marcus AI, Ramalingam SS, Fu H, Gilbert-Ross (2023). Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis. bioRxiv,
- Brat DJ, Aldape K, Bridge JA, Canoll P, Colman H, Hameed MR, Harris BT, Hattab EM, Huse JT, Jenkins RB, Lopez-Terrada DH, McDonald WC, Rodriguez FJ, Souter LH, Colasacco C, Thomas NE, Yount MH, van den Bent MJ, Perry (2022). Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Archives of pathology & laboratory medicine, 146(5), 547-574.
- Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H, Cole PE, Leung D, Allen JE, Ahluwalia MS, Boxerman J, Brown M, Goldin J, Nduom E, Hassan I, Gilbert MR, Mellinghoff IK, Weller M, Chang S, Arons D, Meehan C, Selig W, Tanner K, Yung WKA, van den Bent M, Wen PY, Cloughesy T (2022). Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors. Neuro-oncology, 24, 1219-1229.
- Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich C (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. The Journal of rural health, 38(4), 886-899.
- de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga (2022). Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial. Neuro-oncology, 25, 146-156.
- Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer causes & control, 33(7), 939-950.
- Gelhard S, Maxwell A, Colman H, Cohen AL, Mendez J (2022). Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost-benefit analysis. Journal of neuro-oncology, 159(2), 293-300.
- Wu Z, Rajan S, Chung HJ, Raffeld M, Panneer Selvam P, Schweizer L, Perry A, Samuel D, Giannini C, Ragunathan A, Frosch MP, Marshall MS, Boué DR, Donev K, Neill SG, Fernandes I, Resnick A, Rood B, Cummings TJ, Buckley AF, Szymanski L, Neto OLA, Zach L, Colman H, Cheshier S, Ziskin J, Tyagi M, Capper D, Abdullaev Z, Cimino PJ, Quezado M, Pratt D, Aldape (2022). Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions. Acta neuropathologica, 144(6), 1175-1178.
- Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C, Pytel P, Lopez GY, Colman H, Nasrallah MP, Santi M, Fernandes IL, Nirschl J, Dahiya S, Neill S, Solomon D, Perez E, Capper D, Mani H, Caccamo D, Ball M, Badruddoja M, Chkheidze R, Camelo-Piragua S, Fullmer J, Alexandrescu S, Yeaney G, Eberhart C, Martinez-Lage M, Chen J, Zach L, Kleinschmidt-DeMasters BK, Hefti M, Lopes MB, Nuechterlein N, Horbinski C, Rodriguez FJ, Quezado M, Pratt D, Aldape (2022). Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta neuropathologica, 145, 71-82.
- Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo M (2022). Replicative Instability Drives Cancer Progression. Biomolecules, 12(11),
- Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner (2021). Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Supportive care in cancer, 30(2), 1365-1375.
- Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon D (2021). Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical cancer research, 27(4), 1048-1057.
- Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw (2021). Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical cancer research, 28, 585-593.
- Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H, van den Bent MJ, Wen PY, Alfred Yung WK, Cloughesy TF, Goldin J (2021). Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro-oncology, 23(2), 189-198.
- Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, Lai B, Antipova O, Deng J, Li L, Tommasini-Ghelfi S, Hurley LA, Unruh D, Sharma NV, Kandpal M, Kouri FM, Davuluri RV, Brat DJ, Muzzio M, Glass M, Vijayakumar V, Heidel J, Giles FJ, Adams AK, James CD, Woloschak GE, Horbinski C, Stegh A (2021). A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Science translational medicine, 13(584),
- Holowatyj AN, Viskochil R, Ose D, Tingey B, Haaland B, Wilson D, Larson M, Feltz S, Lewis MA, Colman H, Ulrich C (2021). Diabetes, Body Fatness, and Insulin Prescription Among Adolescents and Young Adults with Cancer. Journal of adolescent and young adult oncology, 10(2), 217-225.
- Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw (2021). Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. Journal for immunotherapy of cancer, 9(7),
- Wang X, Haaland B, Hu-Lieskovan S, Colman H, Holmen S (2021). First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer reports (Hoboken, N.J.), 4(6), e1419.
- Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert (2021). Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-oncology advances, 4(1), 1-10.
- Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent MJ, von Deimling A, Weller (2020). cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta neuropathologica, 139(3), 603-608.
- Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. Journal of neuro-oncology, 148(3), 577-585.
- Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert M (2020). A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro-oncology, 22(10), 1505-1515.
- Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, Venneti S, Baskin-Bey E, Spratt DE, Colman H, Sarkaria JN, Chinnaiyan AM, Eisner JR, Speers C, Lawrence TS, Strowd RE, Wahl D (2020). Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Molecular cancer therapeutics, 19(10), 2163-2174.
- Colman (2020). Adult Gliomas. Continuum (Minneapolis, Minn.), 26(6), 1452-1475.
- Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon K (2019). Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of clinical oncology, 37(9), 741-750.
- Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen P (2019). Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 85(3), E607-E608.
- Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins R (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature medicine, 25(3), 477-486.
- Hummel S, Kohlmann W, Kollmeyer TM, Jenkins R, Sonnen J, Palmer CA, Colman H, Abbott D, Cannon-Albright L, Cohen A (2019). The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC cancer, 19(1), 190.
- Smith-Cohn M, Davidson C, Colman H, Cohen A (2019). Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS oncology, 8(4), CNS48.
- Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. Journal of neurosurgery, 128(4), 1133-1138.
- Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen S (2018). Mutant IDH1 Promotes Glioma Formation In Vivo. Cell reports, 23(5), 1553-1564.
- Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research Network, Camargo F, Liang (2018). Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell reports, 25(5), 1304-1317.e5.
- Ippen FM, Colman H, van den Bent MJ, Brastianos P (2018). Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 38(38), 158-167.
- Colman (2017). Toward more informative biomarker-based clinical trials in glioblastoma. Neuro-oncology, 19(7), 880-881.
- Ceccarelli M, et al. (TCGA Research Network, Colman H (2016). Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 146(3), 550-563.
- Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen MC, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Nageswara Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor M (2016). Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Epub ahead of print]. Journal of clinical oncology, 34(21), 2468-2477.
- Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncology, 18(4), 557-64.
- Karsy M, Guan J, Jensen R, Huang LE, Colman (2016). The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. World neurosurgery, 88, 222-236.
- Cohen AL, Colman (2015). Glioma biology and molecular markers. Cancer treatment and research, 163, 15-30.
- Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang F (2015). Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem cells (Dayton, Ohio), 33(8), 2400-15.
- Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder (2015). Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. The Journal of neuroscience, 35(45), 15097-112.
- The Cancer Genome Atlas Network (2015). Comprehensive and Integrative Genomic Characterization of Diffuse Lower Grade Gliomas DOI: 10.1056/NEJMoa1402121 *Includes Colman, H. The New England journal of medicine, 372(26), 2481-2498.
- Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program., Brain Tumor Trials Collaborative (2015). Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro-oncology, 17(2), 266-73.
- Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, CERN Foundation (2015). Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-oncology, 17(3), 440-7.
- Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent J (2015). Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-oncology, 17(8), 1051-63.
- Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman (2015). Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurgical focus, 38(3), E2.
- Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen R (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurgical focus, 38(3), E4.
- Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H, Jensen RL, Huang L (2015). Intermittent induction of HIF-1¿ produces lasting effects on malignant progression independent of its continued expression. PloS one, 10(4), e0125125.
- Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H, Lee JS, Li XN, Xu RH, Huang P, Wang (2015). Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem cell research & therapy, 6(1), 198.
- Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman (2015). Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget, 6(31), 31007-17.
- Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman (2015). DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta neuropathologica communications, 3, 34.
- Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul (2014). A high Notch pathway activation predicts response to ¿ secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem cells (Dayton, Ohio), 32(1), 301-12.
- Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta M (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England journal of medicine, 370(8), 699-708.
- Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape (2013). Mesenchymal differentiation mediated by NF-¿B promotes radiation resistance in glioblastoma. Cancer cell, 24(3), 331-46.
Review
- Karsy M, Guan J, Cohen A, Colman H, Jensen R (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. Neurosurgery clinics of North America, 27(2), 249-60.
- Chen R, Cohen AL, Colman (2016). Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Current treatment options in oncology, 17(8), 42.
Case Report
- Sivakumar W, Oh N, Cutler A, Colman H, Couldwell W (2015). Cranial and spinal leptomeningeal dissemination in esthesioneuroblastoma: Two reports of distant central nervous system metastasis and rationale for treatment. Surgical neurology international, 6(Suppl 25), S628-32.
Editorial
- Colman (2019). A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. 21(1), 6-7.
Abstract
- deHoll S, Fritz K, Malani R, Colman H, Mendez J (2025). QLTI-08. Single institution experience with romiplostim for chemotherapy-induced thrombocytopenia in Gliomas . 27(Supplement_5), v375.
- Whipple N, Molinaro A, Reddy A, Jaeger-Krause M, Iv M, Villanueva-Meyer J, Lupo J, Cooney T, Raber S, Hoffman C, Jensen J, Prados M, Gartrell R, Kline C, Cheshier S, Mueller S, Colman (2025). CTP-18. PNOC025: A phase 1 study assessing the safety and tolerability of magrolimab in children and adults with recurrent or progressive malignant brain tumors . 27(Supplement_5), v149¿v150.
Other
- Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh (2025). Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature medicine, 31, 3204.
- Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner (2022). Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Supportive care in cancer, 30(2), 1377-1378.
- Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. Research square,
News & Podcasts
Huntsman Cancer Institute News
- Discovery Innovations Winter 2025
- Breakthrough Trial Shows Promising Therapy for Aggressive Brain Cancer
- Highlights of Discovery and Innovation
- Breakthrough in Glioblastoma Treatment with the Help of a Virus
- Clinical Trial Hopes to Shed New Light on Glioblastoma
- Howard Colman, MD, PhD, as Experimental Therapeutics Program Co-Leader
He listens and discusses and explains all of the MRI. Shows empathy.
The BEST!!!!!!!!
Dr Colman cares, and is very capable. I recommend him highly as a neurooncologist.
Extremely knowledgeable, professional, respectful, and highly recommend!
He is a very good oncologist and he knows his stuff. I trust him wholeheartedly for my cancer care.
Awesome dr.!!!
Dr. Colman has always explained things in a way both myself and my husband can comprehend. I've been thru several different cancer therapies and he explained the process, the possible outcomes and that's how things have been going.
He really took time to answer my questions
Dr. Colman is very knowledgeable and I never feel rushed when asking my questions or concerns.
The best care
Very good and knowledgeable doctor
Awesome!
Dr. Colman listens to any concern I have and answers my questions to the best of his ability. I appreciate how concerned he is and providing options to me.
From MD Anderson in TX, did his MD there in Neuroscience and biomedical research for brain cancer. Awesome doctor who is up to date on all that latest research.
Very thorough. Very serious about the care we get and care we get
Dr Colman is so nice, he always takes time to show and explain my MRI scans to me. He listens to me and helps me understand things. I am glad he came to Huntsman clinic hospital
Great doctor
He's the BEST! You can trust him!
Highly trained and communicative on all of the information.
Knowledgeable. Straight to the point. Answers directly
Excellent, efficient care
Dr. Colman is a fabulous doctor. It's not just as education but his kindness and compassion for what you're going through.
Dr Colman explained all the factors about the care I needed with calm and reassurance
Great doctor with a great team
Dr. Colman is very attentive regarding my MRI's and always answers any questions I have.
I have a great deal of respect for Dr. Colman. He's always taken the time to make sure I understand what I'm seeing on my MRI scans and why my treatment is changing.
He was courteous and professional
Terrific at providing great care on an individual basis.
Dr Coleman is a very intelligent and caring man. He explains things to the patient in a way they can understand. He gives options that not only make you feel involved in your care but understood as well. Bottom line he's amazing and I'm lucky to have him as my doctor.
I believe that if there was a doctor that was serious about your diagnosis, He is a scientific expert and has the credentials that prove he can diagnose any type of neurological condition out side of his profession and that is why I have stayed with his team for 14 years and counting.
Dr. Colman is very knowledgeable and he takes his time with each patient.
Professional, respectful, courteous, listened to and answered our questions. Highly recommend!
Excelente trabajo del doctor colman
Dr. Colman is a brilliant Neuro-Oncologist, but he does not understand how to empathize with patients, unfortunately.
Dr Coleman is extremely knowledgeable. He informs you of all possibilities to help your health. He not only takes care of your medical needs but understands your emotional needs as well.
He's an Awesome doctor!
He and his staff are great!
Terrific doctor; very knowledgeable and ready and able to clearly explain answers to all inquiries.
He's very professional and thorough.
great person- very kind
Dr Coleman and his team are excellent to have in your corner
Dr. Colman is a wonderful neuro-oncologist! He listens to you about your concerns and reassures you that how things can work out. I would recommend him to be your neuro-oncologist.
Dr. Colman is great at explaining why and how my treatments are going.
He was a great Dr. Was very knowledgeable. Nice guy !
Howard Colman is the real deal. If you're ever in this incredibly discouraging situation, Dr. Colman is the one I would recommend for the job. His knowledge and determination are very comforting. Most of all, he is kind and empathic in a really really hard situation.
Tremendous understanding of general knowledge surrounding overall issues of my medical situation, and rare ability to apply that understanding to my specific situation--and then to communicate clearly and work together toward a treatment plan. Can recommend without hesitation.
In addition to accomplishing the main purposes of our visit he diagnosed a problem I was having in my mouth that was causing me great difficulty and prescribed medicine for it.
Dr. Colman brought back my hope in this situation. He gave me positive encouragement in my situation. He gave me hope for the future and what it could hold for me. After almost 3 weeks in the hospital and feeling that there was very little hope left for me, his approach to my future care and continuing radiation he gave me my hope back.
First of all, after receiving the medical care from a replacement doctor, they left me on the waiting room for over an hour'Not very happy.
Amazing doctor!
Terrific doctor. Brilliant and clear communicator.
Dr Colman has kept me informed all along the way as new things come up and new treatments are required.
Excellent physician, knowledgable and prompt.
Very knowledgeable and helpful.
Dr. Colman is always very professional and very friendly. I trust him to make proper decisions on my behalf. I feel like I am very lucky to have him as my doctor.
I know Dr Colman has a lot of patients to see, but waiting 1 to 2 hours just for the PA is disappointing.
Dr Colman is always very attentive to my concerns and questions. And he goes into detail with me during my appointments.
Dr Colman is amazing at explaining things to us and always lets us know our options. He is brilliant and his team is awesome too.
Treated me very well!!
Terrific, thoughtful guidance in thinking through complex healthcare decisions.
Dr. Colman is very knowledgeable. He took the time to explain what was going on and made sure all of our questions were answered.
Dr Coleman and his PA Sean are amazing. We feel so lucky to have them on our side through this difficult time. They listen, they recommend, and they give reason to their recommendations.
He explained and showed me the MRI and answered my questions.
Dr Colman is very caring and very professional, we think hes a very Awesome doctor!
blessed beyond expression to have someone not only at the top of his profession, but patient, kind and articulate.
I love Dr. Colman, hes a straight shooter with a dry seen of humor and has always let me know of all my options as things have come up.
Huntsman was great, getting my orders to intermountain Health took time I had call over 5 days to make the appointment for the mri
Dr. Colman is wonderful! He always listens to my symptoms/concerns and is very personable.
Good
I can't say enough about the effect Dr. Colman has had on my life. I trust his expertise and appreciate his thorough, analytical approach.
He and Sean are an amazing team and I trust him implicitly with my care.
He's professional and straightforward. He doesn't rush through the appointment and answers my husband's questions with patience.
Always honest and respectful Great Drs and team.
Dr Coleman is the best oncologist I've ever had. I would recommend him to anyone who needed help.
Lack of communication
Good
They are very good
Very much appreciated reviewing MRI scan with doctor, and the advice regarding "type A" personalities and aging was golden -- both my husband and I benefited from that.Definitely felt like we were in good hands, and in the right hands.
Good
I did not to have a timeline as to the progression of my cancer, but he gave me one despite this. However, my caregivers benefited from the knowledge.
Shawn is very knowledgeable and easy to speak to. He does a great job.
Overall very happy with the care and services we received.
Good
It was a very quick appointment but those are the ones I prefer. Dr. Colman came in, showed me my images from before and after treatment, made sure I was still doing okay and that I didn't have questions and we went on our way. The quicker the appointment at this office the better in my opinion because that means things are going right.
Dr Colman and Dr McKean were very professional and thorough
Allowed my wife to participate via Face Time. That was nice.
Dr. Colman and Sean are who I would recommend to people locally for treatment of brain tumors.
Dr. Coleman has cared for my Mom through 6 years of cancer survival, he and his staff are the very best.
Both Dr McKean and Dr Colman arranged their schedule to see me, because of transportation issues
Care provider was able to easily explain even complicted parts of the proposed treatment,and ensured I understood likely side effects and that it was the direction that I wanted to go with my treatment which made me feel Very comfortable in a situation where so muchh of my life feels outside my controli have alreeady told family members how very pleased I am with my Dr. And wouldn't hesitate in the sliightest to recomend them to somethat I cared about
I absolutely love the physician's I interact with. I have been a patient for a lot of years and have never received anything but the best care. I appreciate the team and all of the staff so much.
Great appointment, very happy with my vsisit
All good.
Good
Doctor didn't review my scans beforehand, forgot what I had been diagnosed with and I had to remind him (he missed an entire tumor recovery area). MRI noted something in the scan that he didn't acknowledge. I am going elsewhere for a second opinion on the matter.
Dr. Colman and Sean Strope are both amazing. They made sure we understood what we discussed, were straight forward when answering our questions, and ensured that they did everything they could to help us in this process. Dr. Colman even took the time to come back in to our room after we were done talking to tell us that about a pathology result that came back during our visit, which I think many other doctors would have just waited to do until our next visit! This result was something that indicated the tumor will be more responsive to treatment and gave us peace of mind, so the fact that he cared enough to take his time and come back in was amazing.
Dr. Coleman seemed to be in a hurry when discussing my MRI and questions. I felt as if I was a general patient he needed to see.
Professional, respectful, provided information, listened to my health questions, and highly recommend.
It is apparent that Dr. Colman and Sean Strope are both very knowledgeable, caring, and thorough. They take every question seriously and never make me feel rushed. I especially appreciate the fact that I am shown all of the MRI imaging so that I can see for myself what we are dealing with. I also appreciate how thorough the explanations are of the tumor board discussions and appreciate the lengths to which everyone at Huntsman goes to collaborate and provide the highest standard of care.
I appreciate everyone's engagement!
Dr Coleman and PA are awesome! Glad to have them!
Dr. Coleman is great!
good
As usual they were all very professional and concerned while including my opinion.
My Dr seemed to be in a hurry during our appointment
I like my drs and their staff
Really glad I have been able to work with Dr. Coleman and Sean, they are very attentive and I trust they have my best interest in hand
Doctor communicated clearly, was easy to talk to, gave me confidence in his understanding of my situation.
HCI Doctor's, Nurses, PA's, and Medical Assistant's are highly recommended and care about my health.
Dr Colman and Dr Strope are the best. They make us feel like [NAME REMOVED] is the most important person they are treating and always go the extra mile to answer any questions or concerns we have. We know they have busy schedules but they never make us feel rushed or uncared for. They have made a hard time easier for [NAME REMOVED].
good
awesome!!!
especially appreciated the PA's attentiveness and expertise
I think I have the best Doctor's available to anyone. thank you
provider suggested several options, but I didn't leave with that information in hand.
positive follow up
Good
Everything about the visit and personnel was like a well-oiled machine...
Everyone was amazing!
Highly recommend! Everyone cares about my current, previous, and future health.
good
good
good explanations were given
good
We were very happy to hear that the course of treatment was also recommended by Dr. Colman and his team. We appreciate the honesty, transparency and explanation of diagnosis that the team offered to us in a way we could understand. Thank you for confirming our treatment plans were exactly what we needed to do.
video visit - it was great.
Dr./care provider gave updates to my current condition, listened to my questions/concerns, included and explaineddecisions, and I highly recommend to others.